Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kimberly Clark Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Kimberly Clark Corp trades at $111.34 (market cap $38.09B). The key difference: Kimberly Clark Corp is far larger — about 8.5× ACADIA Pharmaceuticals Inc.'s market cap, and Kimberly Clark Corp pays a 4.46% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KMB | |
|---|---|---|
Market Cap | $4.49B | $38.09B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $136.77 |
52-Week Low | $20.06 | $93.05 |
Enterprise Value | $3.69B | $44.63B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Kimberly-Clark (KMB) trades at $114.74, up 0.02% on the day, showing stable performance near its consensus price target. The stock maintains a bullish technical signal with strong moving average support, though oscillators indicate potential overbought conditions. Fundamentally, the company demonstrates consistent earnings beats with Q1 2026 EPS of $1.97 exceeding expectations, supported by a healthy 12.8% net income margin and robust ROE of 146.29%. Recent corporate actions include a $1.28 dividend payment scheduled for July 2026.
KMB presents a mixed outlook with strong profitability metrics offset by revenue declines from $20.4B in 2023 to $16.45B in 2025. Investment appeal includes a 5%+ dividend yield and analyst consensus leaning toward Hold (58.06%) with a $109.20 price target. Key risks include margin pressure from input costs and competitive threats from new market entrants like Arbex. Institutional sentiment remains cautious despite technical strength, requiring monitoring of Q2 2026 earnings due August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
